Swedish Orphan Biovitrum

Swedish Orphan Biovitrum (Sobi) is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families.

Sobi’s research and product portfolio is primarily focused on haemophilia, inflammation and genetic and metabolic diseases. They have world-class capabilities in protein biochemistry and biologics manufacturing development – validated by leading industry partners. Their organisation spans 24 countries, delivering therapies to patients in 67 countries across the globe.